Proceedings of the National Academy of Sciences · 31 July 2026 · From issue 15
Blocking antibodies in myasthenia gravis patients raised the risk of severe COVID pneumonia up to 12 times.
Adrian Gervais, Astrid Marchal et al., High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies, Proceedings of the National Academy of Sciences.
Integrity screen: passed (3 checks) Checked 3 August 2026. Read the source
The plain-language reading of this paper is in the full issue, for subscribers.
Read the full issue